An experienced and ambitious team consisting of entrepreneurial minded scientists and technicians builds the foundation of the Research & Development (R&D) team of Cilian AG. In the context of collaboration, feasibility studies and research contracts, this team has already successfully demonstrated the efficiency of the technology platform.

The company benefits from the unique qualification of different specialists in the team, both with academic and industrial background in the areas of molecular and cell biology, fermentation, process engineering and protein biochemistry.


Christian Scheiner

Christian Scheiner (CEO)

Christian Scheiner earned business degrees in Germany and the US and brings to Cilian more than 25 years of experience in the pharmaceutical industry. His tenure in the industry included leading management positions in research based pharmaceutical and biotech companies (Boehringer-Ingelheim); manufacturers of generic pharmaceuticals (STADA Arzneimittel AG); Life Science companies (VITA 34 International AG) and consulting (The Forty To See, Inc.). He possesses substantial international exposure predominantly in Europe and North America. His career included operating business (Sales and Marketing); strategic business (Business Development; M&A) as well as start up / company set up.

At Cilian, Christian Scheiner is responsible for Business Development and Strategy.


Dr. Marcus Hartmann

Dr. Marcus Hartmann (CSO)

Marcus Hartmann has spent his scientific career investigating protozoan organisms, particularly Ciliates. He worked for the central research department of Aventis, Frankfurt (Germany), earned his doctorate (summa cum laude) and was a postdoc in the academic working group of Prof. Tiedtke at the University of Münster. His postdoctoral study dealt with basic research in the field of protozoa and the commercial applications of protozoan organisms, work that was funded by the European Commission. Based on his extensive scientific experience in the field Ciliate biotechnology, Dr. Hartmann founded Cilian in 2001, and since then he has headed the Company’s R&D team and operations.

Marcus Hartmann is the author of numerous scientific publications, recitations, patents and patent application in the area of Ciliate biotechnology. One of the main breakthrough of his team was the first-ever expression of therapeutically usable protein in Ciliates, human DNAse I.


Christian Fründ

Christian Fründ (CFO)

Christian Fründ earned his business degree in Germany. He brings to Cilian extensive experience in public accounting firms. Subsequently he held senior controlling positions in large corporations. He also advises medium sized corporations through Curator Consulting GmbH on assignments such as management support; finance and controlling; mergers and acquisitions, and start-up.

Christian Fründ is CFO and responsible for Finance and Administration.


Cilian’s Supervisory Board consists of three business persons and experts in biotech research, all of which possess entrepreneural experience in high technology and are well connected.

Sebastian Schneberger is an entrepreneur and founder, co-founder and managing director of a set of high technology enterprises in the IT space and serves as chairman of the supervisory board of the Cilian AG.




Professor Dr. Theodor Dingermann, pharmacist and full professor at the University of Frankfurt (Germany), president of the German pharmaceutical society and author of important biotechnological compendiums, is a prominent experts in Germany within the field of expression systems and recombinant therapeutic proteins. Professor Dingermann supports the management in scientific issues.



Michael Arns, is a lawyer in practice in the law firm in Münster, Germany, Arns, Schwering and Tinner with the main focus in the area of national contractual law, business law and criminal law (especially business criminal law and tax criminial law). Michael Arns is lawyer since 1996. He studied law at the University of Münster (WWU) in Münster, Germany, and since that time he is accompanying in the legal area foundation processes of setting up businesses.




Dr. Ingo Aldag received a doctorate at the University of Osnabrück (Germany) and gained extensive experience within the field of the biochemistry of membrane proteins. Dr. Aldag is specialized in the fermentation of Ciliates, the purification and analytics of Ciliates proteins and leads up stream and down stream process development. Moreover he supervises animal studies in collaboration with external academic-medical centers.



Dr. Ulrike Bockau received a doctorate at the University of Münster (Germany). In her past scientific work, Dr. Bockau focused on specific aspects of the expression of recombinant proteins in Ciliates. Dr. Bockau is also specialized in genetics and molecular biology of Ciliates. She leads vector construction and master development.



Dr. Jenny Calow holds a degree in biochemistry and graduated at the department of neurochemistry of the Paul Flechsig Institute (Leipzig, Germany). Subsequently, she worked as a post doc in the department of dermatology at the university of Münster. Her scientific work focused on molecular aspects of neuroinflammation as well as on immunological investigations of immune cells. Dr. Calow is responsible for the biochemical and immunological characterisation of heterologous expressed proteins and supervises in vivo studies.


Dipl.-Ing. (FH) Karina Jawinski received her Diploma Engineer in chemistry at the University of Applied Sciences (Luebeck, Germany), focusing on biotechnology. She is spezialized in the molecular biology of Ciliates and protein biochemical tools. Currently, she is focusing her work on the expression and purification of recombinant antigens in Ciliates, where she supervises proof of principle studies and animal studies with external partners.



The Research Team is supported by Sema Strub.